ARVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arvinas Inc. (ARVN) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock has shown significant recent price declines, weak financial performance, and no clear technical or proprietary trading signals to support an immediate purchase. While there are positive catalysts related to its ARV-102 program and analyst upgrades, these are offset by financial challenges and lack of strong trading sentiment.
The MACD is below 0 and negatively contracting, RSI is neutral at 47.728, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 10.651, with resistance at 11.181 and support at 10.121.
Positive early-stage data for ARV-102 showing potential for Parkinson's disease treatment. Analyst upgrades and raised price targets from Citi, Piper Sandler, and Evercore ISI, citing progress in clinical trials and strategic pivots.
Consensus EPS estimate revised lower by 1.3% over the last 30 days. Lack of significant hedge fund or insider trading activity.
In Q4 2025, revenue dropped by -83.95% YoY to $9.5M. Net income improved but remains negative at -$67.4M, with EPS increasing to -1.04. Gross margin remains at 100%. The company has cash to fund operations into 2028 but faces significant financial challenges.
Analysts have shown optimism, with Citi, Piper Sandler, and Evercore ISI raising price targets to $18-$21 and maintaining Buy/Outperform ratings. However, Wedbush remains Neutral, awaiting further clinical insights.
